Cerebral embolic protection in transcatheter aortic valve implantation (TAVI): a pooled analysis of 4091 patients

Bibliographic Information
Authors: Balata M.; Gbreel M.I.; Elkasaby M.H.; Badran A.S.; Hassan M.; Westenfeld R.; Pfister R.; Zimmer S.; Becher M.U.; Nickenig G.; Sugiura A.
Journal: Cardiovascular Intervention and Therapeutics
Publisher: Springer
Publication Date: 10 May 2025
Volume / Issue: Volume 40 / Issue 3
Pages: 490–505
ISSN: 18684300
DOI: 10.1007/s12928-025-01128-3
Scopus: View on Scopus
PubMed: 40347211
Document Type: Review
Authors and Affiliations
Balata M., Department of Internal Medicine and Cardiology, Friedrich–Alexander University of Erlangen-Nuremberg, Erlangen, Germany; Gbreel M.I., Faculty of Medicine, October 6 University, Giza, Egypt; Elkasaby M.H., Faculty of Medicine, Al-Azhar University, Cairo, Egypt; Badran A.S., Faculty of Medicine, Ain Shams University, Cairo, Egypt; Hassan M., Department of Immunology, Theodor Bilharz Research Institute, Giza, Egypt; Westenfeld R., Department of Internal Medicine and Cardiology, University Hospital Duesseldorf, Düsseldorf, Germany; Pfister R., Department of Internal Medicine and Cardiology, University Hospital Cologne, Cologne, Germany; Zimmer S., Department of Internal Medicine and Polyclinic II, University Hospital Bonn, Bonn, Germany; Becher M.U., Department of Internal Medicine and Cardiology, Friedrich–Alexander University of Erlangen-Nuremberg, Erlangen, Germany; Nickenig G., Department of Internal Medicine and Polyclinic II, University Hospital Bonn, Bonn, Germany; Sugiura A., Department of Internal Medicine and Polyclinic II, University Hospital Bonn, Bonn, Germany
Abstract
Background: Transcatheter aortic valve implantation (TAVI) is increasingly used for severe aortic stenosis, but debris embolization during the procedure can lead to strokes, impacting survival and quality of life. The role of cerebral embolic protection devices (CEPDs) in mitigating stroke risk remains debated. We aim to evaluate the impact of CEPDs on the risk of stroke and neurocognitive outcomes after TAVI. Methods: Six databases (PubMed, Scopus, Web of Science, Cochrane, Embase, and Ovid) were searched until 20 January 2023. Original randomized controlled trials (RCTs) were only included and critically appraised using the Cochrane risk of bias (ROB) tool. Results: Seven RCTs (4091 patients) were analyzed. CEPDs significantly reduced the risk of disabling stroke within 2–5 days post-TAVI (relative risk = 0.455, 95% CI: [0.214, 0.967]; p = 0.041). However, there was no significant difference in disabling stroke risk between the two groups at the 30-day follow-up (relative risk = 1.295, 95% CI: [0.373, 4.493]; p = 0.684). No significant differences were observed in non-disabling or overall stroke rates at 2–5 days, 30 days, or 90 days. Additionally, CEPDs did not significantly affect risks of life-threatening bleeding, major vascular complications, mortality, or acute kidney injury. Conclusion: CEPDs are effective in reducing disabling stroke risk in the immediate post-TAVI period (2–5 days) but did not significantly affect the rates of non-disabling stroke, overall stroke, or disabling stroke after 30 days when compared to non-CEPD use. These findings suggest that CEPDs may offer short-term neuroprotection. © The Author(s) under exclusive licence to Japanese Association of Cardiovascular Intervention and Therapeutics 2025.
Keywords
Cerebral embolic protection; Meta-analysis; Neurological complications; Systematic review; Transcatheter valve implantation; Aortic Valve Stenosis; Embolic Protection Devices; Humans; Intracranial Embolism; Randomized Controlled Trials as Topic; Stroke; Transcatheter Aortic Valve Replacement; acute kidney failure; aged; cerebrovascular accident; clinical effectiveness; controlled study; female; follow up; human; incidence; life threat; male; meta analysis; Montreal cognitive assessment; mortality; National Institutes of Health Stroke Scale; neurological complication; neuroprotection; postoperative complication; postoperative hemorrhage; randomized controlled trial (topic); Review; transcatheter aortic valve implantation; vascular disease; very elderly; adverse event; brain embolism; embolic protection device; etiology; prevention and control; procedures; surgery
Citation Information
Scopus Citations: 6
For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.
The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.
English Website: https://www.tbri.sci.eg/en/
Arabic Website: https://www.tbri.sci.eg/ar/
Prepared and Uploaded by:
Abdalla F. Abdalla
Electronic Portal Unit
